CARsgen Therapeutics is a clinical-stage immune-oncology company that develops a new chimeric T-cell antigen receptor. It offers therapeutics that help liver, lung, stomach and brain cancers treatment. The company has established several in-house platforms including antibody discovery, lentiviral vector production and next-generation CAR-T cell technologies.